The ONLY Thing Trump and Biden Agree On

Just before he left office, former President Donald Trump authorized a massive amount of federal funding for what he saw as an industry now critical to national defense.

And he allocated $142.2 BILLION for research and development in that industry…

But much to everyone’s surprise (or maybe not), when Joe Biden took office, instead of racing to cancel his predecessor’s orders, he doubled down on them.

Now, instead of $142.2 billion, this industry is staring down the barrel of over $227 BILLION in government assistance.

And while both presidents are adamant this industry is critical to our national defense, it’s got nothing to do with guns or ammunition or bombs or tanks.

It’s the one industry in the U.S. that can protect us from our unseen enemy: disease.

COVID Crippled Commandos

A recent Defense Health Agency report showed that COVID-19 was already making the rounds on domestic military bases as early as February 2020, weeks before the first positive cases were identified.

The first case of “community spread” of COVID-19 in the U.S. was in Vacaville, California, right next to Travis Air Force Base, where evacuees from Wuhan were temporarily housed in February 2020.

And before we knew what was happening, people were already dying on and around our military bases.

Ships went into lockdown. Bases did too. If there had been an attack on our country, our defenses would have been weak at best.

And that’s why the biotechnology industry is so critical to the safety of our nation and the people who live here.

That’s our first, last, and only line of defense against viruses and bacteria that intend to do us harm — be they naturally occurring or born in a lab.

And that’s why it’s not just the U.S. government pouring money into research and development. In fact, that $227 billion I mentioned earlier is just the tip of the iceberg.

Overall, global spending on biotechnology R&D is projected to surpass $7 TRILLION this year alone.

Literally at no time in history has there been so much money flowing into such a small market in such a short period of time.

And that’s where the opportunity lies for investors who see what’s coming now and position themselves correctly.

Tiny but Powerful

When I was younger, I had a red Toyota Tacoma two-seater pickup truck. I loved that truck. It was one of the best vehicles I’ve ever owned. It was a 4×4. And it only had a four-cylinder engine. But those cylinders were the size of paint cans and it displaced 2.7 liters (more than my buddy’s V6 Ford Bronco II).

It was tiny, but it was powerful. And I’ll never forget the time the owner of a Humvee told me exactly that. He’d stopped to watch me try to pull a fully loaded work truck out of a ditch one snowy afternoon.

I’m guessing he thought he’d get a good laugh watching the tiny Tacoma try to tug the massive truck.

But he was in for a surprise. Tank (that’s what I named the truck) squatted down and ripped that other guy right out of the ditch.

“Dang, man. That truck’s tiny, but it sure is powerful!”

And that’s the kind of companies the funding I was just talking about is going to flow to. They’re still tiny because they haven’t created a successful drug yet.

But they’re powerful enough to become the next AstraZeneca, Merck, or Pfizer…

Especially when that $7 TRILLION in funding hits.

Backing the Right Horse

But the thing that’s probably holding investors back right now is that it’s so hard to tell which companies are going to take that funding and make a successful medicine from it.

And there are a lot of tiny biotech companies out there. Which ones are the “tiny but powerful” ones?

Which are going to reward early investors and which are going to fail? It’s a tough call to make unless you know how to “handicap” the horses in the race.

But if you’ve got a system you can use to evaluate the companies, their therapies, and the chance they’ll get FDA approval, well, then you’ve got a near surefire way to capture the majority of the gains that $7 TRILLION in medical funding is going to drive.

Fortunately for you, you don’t have to have one… because my colleague, Keith Kohl already created one. What’s more, it’s already identified several companies poised to deliver massive returns.

I’m talking about the kind of investments that could turn a cheeseburger into a T-bone, a pair of roller skates into a Ferrari, and a camping tent into a penthouse apartment.

And the best part: He’s offering to share his research with you today.

A Winning Formula

You see, Keith has been immersed in the biotech market for years. And throughout the countless hours he’s spent researching companies and their potential medicines, he noticed a pattern.

Through near endless backtesting, he confirmed the pattern existed and could have delivered blockbuster gains to anyone following it. But past performance isn’t indicative of future results.

So he needed a way to make sure the pattern that had existed still did. And there’s only one way to do that: Put some real money on the line and you test your theory.

And it turns out he was right. That pattern he noticed and the system he developed to spot it early on has already delivered unprecedented success for him and his investment community.

They’ve had the opportunity to close out numerous triple-digit gains. And those gains came in periods of just two weeks, four weeks, or three months.

When you develop a system that can do that, you’ve really accomplished something. And that’s just what Keith has done in the biotech industry.

My Personal Invitation to You

Now, I’m not one to ignore success like the kind Keith and his investors are having. And I’m certainly not one to want to keep success like that to myself.

Fortunately for you, neither is Keith. And like I said earlier, his system recently identified several companies that are on the verge of MAJOR medical breakthroughs.

One of them even looks like it could easily turn a thousand bucks into over $77K. Like I said, it’s equivalent to turning a pair of roller skates into a Ferrari.

So Keith put together a presentation for me to share with you today…

In it, you’ll learn all about the stocks his system has identified. You’ll see the data-driven methods he uses to predict FDA approvals. Plus, you’ll learn how to time your investments to perfectly capitalize on those approvals.

But most of important of all, you’ll learn how you can get invested in the companies Keith’s already uncovered.

He created the system. It identified the stocks. I’m providing the connection. All you have to do is take a few minutes out of your day and then make some investments.

How’s that for a helpful hand building up your own personal fortune through biotech investments?

But you have to take that final action and set yourself up for the gains. All Keith and I can do is tell you about the opportunity.

Will you capitalize on it? That’s up to you.

To your wealth,

Jason Williams

@TheReal_JayDubs

Angel Research on Youtube

After graduating Cum Laude in finance and economics, Jason designed and analyzed complex projects for the U.S. Army. He made the jump to the private sector as an investment banking analyst at Morgan Stanley, where he eventually led his own team responsible for billions of dollars in daily trading. Jason left Wall Street to found his own investment office and now shares the strategies he used and the network he built with you. Jason is the founder of Main Street Ventures, a pre-IPO investment newsletter; the founder of Future Giants, a nano cap investing service; and authors The Wealth Advisory income stock newsletter. He is also the managing editor of Wealth Daily. To learn more about Jason, click here.

Want to hear more from Jason? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.